nach oben

Supportive Care in Cancer

Erschienen in:

01.10.2014 | Original Article

Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study

verfasst von: B. Linot, P. Augereau, R. Breheret, L. Laccourreye, O. Capitain

Erschienen in: Supportive Care in Cancer | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Induction chemotherapy with docetaxel-cisplatin and 5-fluorouracil (DCF) for locally advanced head and neck cancers (HNC) is associated with a high risk of severe neutropenia or febrile neutropenia (FN). We conducted a retrospective study to evaluate the efficacy and safety of administering granulocyte colony-stimulating factor (G-CSF) on day 3 (D3) during chemotherapy (early G-CSF stimulation) versus after the end of chemotherapy, as per current guidelines (i.e., after the end of 5-FU perfusion; D7), and its impact on patient outcomes.

Patients and methods

Patients ≥19 years old, with advanced HNC who received DCF induction chemotherapy (D and P 75 mg per meter squared (mg/m²) on day 1 and 5-FU 750 mg/m²/day from D1 to D5), were included in the analysis.

Results

Data of 70 patients were analyzed from 01 January 2003 to 01 December 2010. Mean age was 56 years (range 45 to 77 years). Thirty-six patients (51.4 %) received pegfilgrastim on D7, and 28 (40 %) started G-CSF prophylaxis during chemotherapy; 12 (17.1 %) had daily filgrastim and 16 (22.9 %) pegfilgrastim on D3. Overall response rate (ORR) was 89.6 % (three early deaths due to infectious complications; 4.3 %). The 3-year overall survival (OS) rate was 72.8 %. FN rate was 14.3 % and chemotherapy delay was 12.9 %. In the D7 G-CSF arm, incidence of grade 3–4 neutropenia (p = 0.023), FN (p = 0.029), and cycle delays (p = 0.006) was statistically higher than the “early” G-CSF arm. A decrease of OS was observed at 2 years (from 85.1 to 63.5 %) of chemotherapy discontinuation or FN (p = 0.0348).

Discussion

Early administration of G-CSF is safe and seems to be more effective than D7. Future prospective trials are required to confirm our results.

Sturgis EM (2011) The International Head and Neck Cancer Epidemiology consortium. Head Neck 33(1):141PubMedCrossRef

Zorat PL, Paccagnella A, Cavaniglia G et al (2004) Randomized phase III trial of neoadjuvant chemotherapy in head and neck: 10 year follow up. J Natl Cancer Inst 94:1714–1717CrossRef

Lorch JH, Posner MR, Wirth LJ et al (2008) Induction chemotherapy in locally advanced head and neck cancer. A new standard of care? Hematol Oncol Clin N Am 22:115–163CrossRef

Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506PubMedCrossRef

Paccagnella A, Ghi MG, Loreggian L et al (2010) Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 21:1515–1522PubMedCrossRef

Hitt R, Grau JJ, Lopez-Pousa A et al (2009) Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 27 (15 suppl abstr 6009)

Bonnin N, Ceruse P, Bachelot T, et al (2008) Efficacy of neoadjuvant TPF (nTPF; docetaxel, T; cisplatin, P; 5FU) in nonselected patients (pts) with head and neck cancer and subsequent radiotherapy (RT) combined with chemotherapy (CT) or cetuximab (Cx). J Clin Oncol 26 (suppl2 0, abstr 6074).

Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715PubMedCrossRef

Vermorken JB, Remenar E, van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704PubMedCrossRef

10.

Paccagnella A, Mastromauro C, D’Amanzo P, Ghi M (2010) G. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future? Oncologist 15:8–12PubMedCrossRef

11.

Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205PubMedCrossRef

12.

Crawford J, Althaus B, Armitage J et al (2007) National Comprehensive Cancer Network (NCCN). Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 5:188–202

13.

Holmes FA, O’Shaughnessy JA, Vukelja S et al (2002) Blinded, randomized multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer. J Clin Oncol 20:727–731PubMedCrossRef

14.

Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358(1):36–46PubMedCrossRef

15.

Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267PubMedCrossRef

16.

Hoffman PS (2005) Administration of pegfilgrastim on the same-day or next-day of chemotherapy. J Clin Oncol 23 (Suppl 16, Abstr 8137).

17.

Belani CP, RamalingamS, Al-janadi A, et al (2006) A randomized double-blind phase 2 study to evaluate same-day vs. next-day administration of pegfilgrastim with carboplatin and docetaxel in patients with NSCLC. J Clin Oncol 24 (Suppl 18, Abstr 7110).

18.

Lokich J (2005) Same-day pegfilgrastim and chemotherapy. Cancer Investig 23:573–576CrossRef

19.

Shuman I, Lambrou N, Robson K et al (2009) Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer. J Support Oncol 7:225–228

20.

Matthews KS, Shipman KA et al (2009) The safety and efficacy of day 1 versus day 2 administration of pegfilgrastim in patients receiving myelosuppressive chemotherapy for gynecologic malignancies. Gynecol Oncol 112(3):601–604PubMedCrossRef

21.

Saven A, Schwartzberg L, Kaywin P, et al (2006) Randomized double-blind, phase 2 study evaluating same-day vs. next-day administration of pegfilgrastim with R-CHOP in non-Hodgkin’s lymphoma patients. J Clin Oncol 24 (suppl 18, Abstr 7570).

22.

Lokich JJ (2006) Same-day pegfilgrastim and CHOP chemotherapy for non Hodgkin lymphoma. Am J Clin Oncol 29:361–363PubMedCrossRef

23.

Bohlius J, Cameron DA et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8–32PubMedCrossRef

Titel: Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study
verfasst von: B. Linot
P. Augereau
R. Breheret
L. Laccourreye
O. Capitain
Publikationsdatum: 01.10.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 10/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-014-2270-8

Neu im Fachgebiet Onkologie

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study

Abstract

Background

Patients and methods

Results

Discussion

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Patients and methods

Results

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

Erratum to: “We all talk about it as though we’re thinking about the same thing.” Healthcare professionals’ goals in the management of pain due to advanced cancer: a qualitative study

Bridging cross-cultural gaps: monitoring herbal use during chemotherapy in patients referred to integrative medicine consultation in Israel

Response to Letter to the Editor: “Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study”

Low-level laser therapy for osteonecrotic lesions: effects on osteoblasts treated with zoledronic acid

Oral evaluation and procedures performed by dentists in patients admitted to the intensive care unit of a cancer center

Nationwide population-based cohort study on the association of acute coronary syndrome in patients with malignancies

Neu im Fachgebiet Onkologie

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Manche Gestagene können das Risiko für Meningeome erhöhen

Einladung zum PSA-Screening senkt die Krebssterblichkeit

Update Onkologie